CA2330838C - Neisseria meningitidis antigens and compositions - Google Patents

Neisseria meningitidis antigens and compositions Download PDF

Info

Publication number
CA2330838C
CA2330838C CA2330838A CA2330838A CA2330838C CA 2330838 C CA2330838 C CA 2330838C CA 2330838 A CA2330838 A CA 2330838A CA 2330838 A CA2330838 A CA 2330838A CA 2330838 C CA2330838 C CA 2330838C
Authority
CA
Canada
Prior art keywords
protein
seq
pep
sequence
orf
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CA2330838A
Other languages
English (en)
French (fr)
Other versions
CA2330838A1 (en
Inventor
Claire Fraser
Cesira Galeotti
Guido Grandi
Erin Hickey
Vega Masignani
Marirosa Mora
Jeremy Petersen
Mariagrazia Pizza
Rino Rappuoli
Giulio Ratti
Enzo Scalato
Maria Scarselli
Herve Tettelin
J. Craig Venter
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GlaxoSmithKline Biologicals SA
Original Assignee
GlaxoSmithKline Biologicals SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27574612&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA2330838(C) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by GlaxoSmithKline Biologicals SA filed Critical GlaxoSmithKline Biologicals SA
Priority to CA002650642A priority Critical patent/CA2650642A1/en
Publication of CA2330838A1 publication Critical patent/CA2330838A1/en
Application granted granted Critical
Publication of CA2330838C publication Critical patent/CA2330838C/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/22—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Neisseriaceae (F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/095—Neisseria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/806—Antigenic peptides or proteins
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/82—Proteins from microorganisms
    • Y10S530/825—Bacteria

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA2330838A 1998-05-01 1999-04-30 Neisseria meningitidis antigens and compositions Expired - Lifetime CA2330838C (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CA002650642A CA2650642A1 (en) 1998-05-01 1999-04-30 Neisseria meningitidis antigens and compositions

Applications Claiming Priority (17)

Application Number Priority Date Filing Date Title
US8375898P 1998-05-01 1998-05-01
US60/083,758 1998-05-01
US9486998P 1998-07-31 1998-07-31
US60/094,869 1998-07-31
US9906298P 1998-09-02 1998-09-02
US9899498P 1998-09-02 1998-09-02
US60/098,994 1998-09-02
US60/099,062 1998-09-02
US10379498P 1998-10-09 1998-10-09
US10374998P 1998-10-09 1998-10-09
US10379698P 1998-10-09 1998-10-09
US60/103,796 1998-10-09
US60/103,749 1998-10-09
US60/103,794 1998-10-09
US12152899P 1999-02-25 1999-02-25
US60/121,528 1999-02-25
PCT/US1999/009346 WO1999057280A2 (en) 1998-05-01 1999-04-30 Neisseria meningitidis antigens and compositions

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CA002650642A Division CA2650642A1 (en) 1998-05-01 1999-04-30 Neisseria meningitidis antigens and compositions

Publications (2)

Publication Number Publication Date
CA2330838A1 CA2330838A1 (en) 1999-11-11
CA2330838C true CA2330838C (en) 2018-12-04

Family

ID=27574612

Family Applications (2)

Application Number Title Priority Date Filing Date
CA2330838A Expired - Lifetime CA2330838C (en) 1998-05-01 1999-04-30 Neisseria meningitidis antigens and compositions
CA002650642A Expired - Lifetime CA2650642A1 (en) 1998-05-01 1999-04-30 Neisseria meningitidis antigens and compositions

Family Applications After (1)

Application Number Title Priority Date Filing Date
CA002650642A Expired - Lifetime CA2650642A1 (en) 1998-05-01 1999-04-30 Neisseria meningitidis antigens and compositions

Country Status (16)

Country Link
US (9) US7576176B1 (https=)
EP (23) EP2261352A3 (https=)
JP (9) JP5102414B2 (https=)
CN (3) CN1210305C (https=)
AT (2) ATE388230T1 (https=)
AU (1) AU761780B2 (https=)
BR (1) BR9910089A (https=)
CA (2) CA2330838C (https=)
CY (2) CY1109649T1 (https=)
DE (2) DE69938302T2 (https=)
DK (2) DK1645631T3 (https=)
ES (3) ES2537575T3 (https=)
MX (4) MX339406B (https=)
NZ (4) NZ527182A (https=)
PT (3) PT1093517E (https=)
WO (1) WO1999057280A2 (https=)

Families Citing this family (204)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997025429A1 (en) 1996-01-04 1997-07-17 Rican Limited Helicobacter pylori bacterioferritin
EP2298900A1 (en) 1996-09-17 2011-03-23 Novartis Vaccines and Diagnostics, Inc. Compositions and methods for treating intracellular diseases
US6914131B1 (en) 1998-10-09 2005-07-05 Chiron S.R.L. Neisserial antigens
CN1263854C (zh) * 1997-11-06 2006-07-12 启龙股份公司 奈瑟球菌抗原
US20070026021A1 (en) * 1998-05-01 2007-02-01 Chiron S.R.I. Neisseria meningitidis antigens and compositions
EP2261352A3 (en) * 1998-05-01 2012-01-04 Novartis Vaccines and Diagnostics, Inc. Neisseria meningitidis antigens and compositions
US6756493B1 (en) 1998-09-01 2004-06-29 Antex Biologics, Inc. Nucleic acid sequence and uses thereof
US6693186B2 (en) 1998-09-01 2004-02-17 Antex Biologics Inc Neisseria meningitidis polypeptide, nucleic acid sequence and uses thereof
US6610306B2 (en) 1998-10-22 2003-08-26 The University Of Montana OMP85 protein of neisseria meningitidis, compositions containing the same and methods of use thereof
GB9826886D0 (en) * 1998-12-07 1999-01-27 Smithkline Beecham Biolog Novel compounds
ATE527360T1 (de) 1998-12-08 2011-10-15 Glaxosmithkline Biolog Sa Neue verbindungen abgeleitet von neisseria meningitidis
CA2359486A1 (en) * 1999-01-15 2000-07-20 Smithkline Beecham Biologicals S.A. Neisseria meningitidis polypeptide basb052
EP1144643A1 (en) 1999-01-15 2001-10-17 SMITHKLINE BEECHAM BIOLOGICALS s.a. Neisseria meningitidis antigen
CA2360658A1 (en) * 1999-01-22 2000-07-27 Smithkline Beecham Biologicals S.A. Neisseria meningitidis antigenic polypeptides, corresponding polynucleotides and protective antibodies
CA2360667A1 (en) 1999-01-22 2000-07-27 Smithkline Beecham Biologicals S.A. Neisseria meningitidis basb054 polypeptides and encoding polynucleotides and uses thereof
GB9902084D0 (en) * 1999-01-29 1999-03-24 Smithkline Beecham Biolog Novel compounds
GB9902937D0 (en) * 1999-02-10 1999-03-31 Smithkline Beecham Biolog Novel compounds
JP4812942B2 (ja) * 1999-02-26 2011-11-09 ノバルティス ヴァクシンズ アンド ダイアグノスティクス エスアールエル ＣＧモチーフを含むオリゴヌクレオチドを用いるＮｅｉｓｓｅｒｉａ抗原殺菌活性の増強
CA2365102A1 (en) * 1999-03-12 2000-09-21 Smithkline Beecham Biologicals S.A. Neisseria meningitidis antigenic polypeptides and encoding polynucleotides and uses thereof
AU2004240199B2 (en) * 1999-04-30 2007-05-17 Novartis Vaccines And Diagnostics S.R.L. Conserved Neisserial antigens
JP2003518363A (ja) 1999-04-30 2003-06-10 カイロン エセ．ピー．アー． 保存されたナイセリア抗原
EP2270173B1 (en) * 1999-05-19 2016-01-06 GlaxoSmithKline Biologicals SA Combination neisserial compositions
GB9911683D0 (en) * 1999-05-19 1999-07-21 Chiron Spa Antigenic peptides
AU2013200678B2 (en) * 1999-05-19 2014-08-21 Glaxosmithkline Biologicals S.A. Combination Neisserial compositions
AU2013203304B2 (en) * 1999-05-19 2014-10-09 Glaxosmithkline Biologicals S.A. Combination Neisserial compositions
GB9918319D0 (en) 1999-08-03 1999-10-06 Smithkline Beecham Biolog Vaccine composition
AU2003271337B2 (en) * 1999-08-03 2005-07-21 Smithkline Beecham Biologicals S.A. Vaccine composition
RU2281956C2 (ru) 1999-10-29 2006-08-20 Чирон С.Р.Л. Антигенные пептиды neisseria
GB9928196D0 (en) * 1999-11-29 2000-01-26 Chiron Spa Combinations of B, C and other antigens
CA2390344C (en) 1999-11-29 2014-08-26 Chiron Spa 85kda neisserial antigen
PT2289545T (pt) * 2000-01-17 2016-09-06 Glaxosmithkline Biologicals Sa Vacina de omv suplementada contra meningococos
PL216780B1 (pl) 2000-01-25 2014-05-30 Univ Queensland Of Santa Lucia Wyizolowane białka zawierające konserwatywne obszary antygenu powierzchniowego NhhA z Neisseria meningitidis, białka fuzyjne, kompozycja farmaceutyczna, przeciwciało monoklonalne lub wiążący antygen fragment przeciwciała monoklonalnego, wyizolowany kwas nukleinowy, konstrukt ekspresyjny, komórka gospodarza, sposób wytwarzania rekombinowanego białka, sposób wykrywania N. meningitidis w próbce biologicznej, sposób diagnozowania zakażenia N. meningitidis oraz sposób wykrywania N. meningitidis w próbce biologicznej uzyskanej od pacjenta oraz zastosowanie wyizolowanego białka, białka fuzyjnego i konstruktu ekspresyjnego
ES2281409T3 (es) 2000-02-28 2007-10-01 Novartis Vaccines And Diagnostics S.R.L. Expresion heterologa de proteinas de neisseria.
US6936261B2 (en) 2000-07-27 2005-08-30 Children's Hospital & Research Center At Oakland Vaccines for broad spectrum protection against diseases caused by Neisseria meningitidis
DK1328543T3 (da) 2000-10-27 2009-11-23 Novartis Vaccines & Diagnostic Nukleinsyrer og proteiner fra streptococcus-gruppe A & B
WO2002060936A2 (en) * 2001-01-31 2002-08-08 University Of Iowa Research Foundation Vaccine and compositions for the prevention and treatment of neisserial infections
US7261901B2 (en) 2001-01-31 2007-08-28 University Of Iowa Research Foundation Vaccine and compositions for the prevention and treatment of neisserial infections
GB0103171D0 (en) 2001-02-08 2001-03-28 Smithkline Beecham Biolog Vaccine composition
GB0107661D0 (en) 2001-03-27 2001-05-16 Chiron Spa Staphylococcus aureus
GB0107658D0 (en) 2001-03-27 2001-05-16 Chiron Spa Streptococcus pneumoniae
CN1306956C (zh) * 2001-04-17 2007-03-28 希龙公司 诱导功能活性抗体的脑膜炎球菌b抗原表位的分子模拟物
AU2002303330B2 (en) 2001-05-31 2008-07-24 Novartis Vaccines And Diagnostics, Inc. Chimeric alphavirus replicon particles
GB0115176D0 (en) 2001-06-20 2001-08-15 Chiron Spa Capular polysaccharide solubilisation and combination vaccines
GB0118249D0 (en) 2001-07-26 2001-09-19 Chiron Spa Histidine vaccines
BR0211494A (pt) 2001-07-27 2004-08-17 Chiron Srl Adesinas de meningococo nada, app e orf 40
GB0121591D0 (en) * 2001-09-06 2001-10-24 Chiron Spa Hybrid and tandem expression of neisserial proteins
AU2012202488B2 (en) * 2001-09-06 2014-01-16 Glaxosmithkline Biologicals S.A. Hybrid and tandem expression of Neisserial proteins
AR045702A1 (es) * 2001-10-03 2005-11-09 Chiron Corp Composiciones de adyuvantes.
CN100354297C (zh) * 2001-10-03 2007-12-12 希龙公司 辅助的脑膜炎球菌组合物
US7838015B2 (en) * 2001-10-03 2010-11-23 Novartis Vaccines And Diagnostics, Inc. Adjuvanted meningococcus compositions
MX339524B (es) * 2001-10-11 2016-05-30 Wyeth Corp Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica.
CN100515494C (zh) 2001-12-12 2009-07-22 启龙有限公司 抗沙眼衣原体的免疫
EP2572707A3 (en) 2002-02-20 2013-11-06 Novartis Vaccines and Diagnostics, Inc. Microparticles with adsorbed polypeptide-containing molecules
EP1524991A1 (en) 2002-08-02 2005-04-27 GlaxoSmithKline Biologicals S.A. Vaccine composition comprising transferrin binding protein and hsf from gram negative bacteria
GB0220194D0 (en) 2002-08-30 2002-10-09 Chiron Spa Improved vesicles
US7785608B2 (en) 2002-08-30 2010-08-31 Wyeth Holdings Corporation Immunogenic compositions for the prevention and treatment of meningococcal disease
HUE031886T2 (en) 2002-10-11 2017-08-28 Glaxosmithkline Biologicals Sa Polypeptide vaccines for extensive protection against hypervirulent meningococcal lines
EP2395073B1 (en) 2002-11-01 2017-09-06 GlaxoSmithKline Biologicals S.A. Drying process
US7807802B2 (en) 2002-11-12 2010-10-05 Abbott Lab Polynucleotides for the amplification and detection of Chlamydia trachomatis and Neisseria gonorrhoeae
EP1562982B1 (en) 2002-11-15 2010-05-05 Novartis Vaccines and Diagnostics S.r.l. Unexpected surface proteins in neisseria meningitidis
GB0227346D0 (en) * 2002-11-22 2002-12-31 Chiron Spa 741
AU2003299994A1 (en) 2002-12-27 2004-07-29 Chiron Corporation Immunogenic compositions containing phospholpid
ES2461350T3 (es) 2003-01-30 2014-05-19 Novartis Ag Vacunas inyectables contra múltiples serogrupos de meningococos
US7893096B2 (en) 2003-03-28 2011-02-22 Novartis Vaccines And Diagnostics, Inc. Use of small molecule compounds for immunopotentiation
GB0308198D0 (en) 2003-04-09 2003-05-14 Chiron Srl ADP-ribosylating bacterial toxin
MXPA05011110A (es) * 2003-04-16 2006-01-24 Wyeth Corp Composiciones inmunogenicas novedosas para la prevencion y tratamiento de un padecimiento originado por meningococos.
US7731967B2 (en) 2003-04-30 2010-06-08 Novartis Vaccines And Diagnostics, Inc. Compositions for inducing immune responses
EP1631264B8 (en) 2003-06-02 2017-05-24 GlaxoSmithKline Biologicals SA Immunogenic compositions based on microparticles comprising adsorbed toxoid and a polysaccharide-containing antigen
WO2005019265A1 (en) 2003-08-13 2005-03-03 Chiron Corporation Improved method of purifying tfpi and tfpi analogs
CN103357002A (zh) 2003-10-02 2013-10-23 诺华疫苗和诊断有限公司 多种脑膜炎球菌血清群的液体疫苗
GB0323103D0 (en) 2003-10-02 2003-11-05 Chiron Srl De-acetylated saccharides
CU23236A1 (es) * 2003-12-03 2007-09-26 Ct Ingenieria Genetica Biotech PROTEINA NMB0928 Y SU USO EN FORMULACIONES FARMACéUTICAS P
CU23237A1 (es) * 2003-12-03 2007-09-26 Ct Ingenieria Genetica Biotech PROTEINA NMB1125 Y SU USO EN FORMULACIONES FARMACéUTICAS
GB0408977D0 (en) 2004-04-22 2004-05-26 Chiron Srl Immunising against meningococcal serogroup Y using proteins
WO2006115509A2 (en) 2004-06-24 2006-11-02 Novartis Vaccines And Diagnostics Inc. Small molecule immunopotentiators and assays for their detection
EP1612218B1 (en) * 2004-06-29 2008-05-14 Center for Disease Control Department of Health Taiwan Surface protein of Neisseria bacteria
EP1784211A4 (en) 2004-07-29 2010-06-30 Novartis Vaccines & Diagnostic IMMUNOGENIC COMPOSITIONS FOR GRAMPOSITIVE BACTERIA SUCH AS STREPTOCOCCUS AGALACTIAE
GB0419408D0 (en) 2004-09-01 2004-10-06 Chiron Srl 741 chimeric polypeptides
GB0419918D0 (en) * 2004-09-08 2004-10-13 Imp College Innovations Ltd Vaccine
ES2616294T3 (es) 2005-01-27 2017-06-12 Children's Hospital & Research Center At Oakland Vacunas de vesículas basadas en GNA1870 para protección de amplio espectro contra enfermedades provocadas por Neisseria meningitidis
GB0502095D0 (en) 2005-02-01 2005-03-09 Chiron Srl Conjugation of streptococcal capsular saccharides
GB0502096D0 (en) 2005-02-01 2005-03-09 Chiron Srl Purification of streptococcal capsular polysaccharide
AU2006214064B2 (en) 2005-02-18 2012-04-26 J. Craig Venter Institute, Inc. Proteins and nucleic acids from meningitis/sepsis-associated escherichia coli
NZ599345A (en) 2005-02-18 2013-07-26 Novartis Vaccines & Diagnostic Immunogens from uropathogenic Escherichia Coli
GB0505996D0 (en) 2005-03-23 2005-04-27 Glaxosmithkline Biolog Sa Fermentation process
EP1723964A1 (en) * 2005-05-20 2006-11-22 Institut Pasteur Use of penicillin-binding proteins or polynucleotides or antibodies thereof for preventing or treating bacterial infections
CA2626253A1 (en) 2005-10-18 2007-04-26 Novartis Vaccines And Diagnostics, Inc. Mucosal and systemic immunizations with alphavirus replicon particles
CA2630220C (en) 2005-11-22 2020-10-13 Doris Coit Norovirus and sapovirus antigens
GB0524066D0 (en) 2005-11-25 2006-01-04 Chiron Srl 741 ii
WO2007066226A2 (en) * 2005-12-06 2007-06-14 Universita Degli Studi Di Padova Methods and compositions relating to adhesins as adjuvants
US20090317421A1 (en) 2006-01-18 2009-12-24 Dominique Missiakas Compositions and methods related to staphylococcal bacterium proteins
CA2646539A1 (en) 2006-03-23 2007-09-27 Novartis Ag Imidazoquinoxaline compounds as immunomodulators
CU23572A1 (es) * 2006-03-31 2010-09-30 Ct Ingenieria Genetica Biotech Composición farmacéutica que comprende la proteína nmb0938
AU2014268186C1 (en) * 2006-04-26 2017-12-07 Wyeth Llc Novel formulations which stabilize and inhibit precipitation of immunogenic compositions
AU2016204760A1 (en) * 2006-04-26 2016-07-28 Wyeth Llc Novel formulations which stabilize and inhibit precipitation of immunogenic compositions
DE602007003596D1 (de) 2006-06-12 2010-01-14 Glaxosmithkline Biolog Sa Impfstoff
CA2656474A1 (en) 2006-06-29 2008-01-03 Novartis Ag Polypeptides from neisseria meningitidis
WO2008020330A2 (en) 2006-08-16 2008-02-21 Novartis Ag Immunogens from uropathogenic escherichia coli
AR064642A1 (es) * 2006-12-22 2009-04-15 Wyeth Corp Polinucleotido vector que lo comprende celula recombinante que comprende el vector polipeptido , anticuerpo , composicion que comprende el polinucleotido , vector , celula recombinante polipeptido o anticuerpo , uso de la composicion y metodo para preparar la composicion misma y preparar una composi
GB0700562D0 (en) 2007-01-11 2007-02-21 Novartis Vaccines & Diagnostic Modified Saccharides
GB0713880D0 (en) 2007-07-17 2007-08-29 Novartis Ag Conjugate purification
CA2699513C (en) 2007-09-12 2018-03-13 Novartis Ag Gas57 mutant antigens and gas57 antibodies
WO2009050586A1 (en) 2007-10-19 2009-04-23 Novartis Ag Meningococcal vaccine formulations
US8466259B2 (en) 2007-12-07 2013-06-18 National Health Research Institutes Adjuvants
EP3067048B1 (en) 2007-12-07 2018-02-14 GlaxoSmithKline Biologicals SA Compositions for inducing immune responses
US8426163B2 (en) 2007-12-07 2013-04-23 National Health Research Institutes Production of lipidated proteins in E. coli
US7833776B2 (en) * 2007-12-12 2010-11-16 National Health Research Institutes Lipidating sequences and use thereof for producing lipidated proteins in E. coli
PL2235046T3 (pl) 2007-12-21 2012-12-31 Novartis Ag Zmutowane formy streptolizyny O
CN102356089B (zh) 2008-02-21 2014-02-19 诺华股份有限公司 脑膜炎球菌fHBP多肽
PT2268618E (pt) 2008-03-03 2015-10-12 Novartis Ag Compostos e composições moduladores da actividade tlr
ES2557282T3 (es) 2008-03-10 2016-01-25 Children's Hospital & Research Center At Oakland Proteínas quiméricas de unión al factor H (fHBP) que contienen un dominio B heterólogo, y métodos de uso
WO2009143168A2 (en) * 2008-05-19 2009-11-26 Novartis Ag Vaccine assays
US20100105875A1 (en) * 2008-06-09 2010-04-29 Maria Scarselli Antibodies against neisserial factor H binding protein
GB0810742D0 (en) * 2008-06-12 2008-07-16 Univ Nottingham Enzyme
WO2010028096A2 (en) 2008-09-03 2010-03-11 Children's Hospital & Research Center At Oakland Peptides presenting an epitope of an a domain of factor h binding protein and methods of use
GB0816447D0 (en) * 2008-09-08 2008-10-15 Glaxosmithkline Biolog Sa Vaccine
SI2349520T1 (sl) 2008-10-27 2016-08-31 Glaxosmithkline Biologicals S.A. Postopek čiščenja za ogljikohidrat iz Streptococcus skupine A
JP2012512240A (ja) 2008-12-17 2012-05-31 ノバルティス アーゲー ヘモグロビン受容体を含む髄膜炎菌ワクチン
AU2010203223B9 (en) 2009-01-05 2015-10-08 Epitogenesis Inc. Adjuvant compositions and methods of use
CN102481349B (zh) 2009-01-12 2014-10-15 诺华股份有限公司 抗革兰氏阳性细菌疫苗中的Cna_B结构域
HUE049695T2 (hu) 2009-03-24 2020-10-28 Glaxosmithkline Biologicals Sa Adjuváló H meningococcus faktort kötõ fehérje
EP3017826A1 (en) 2009-03-24 2016-05-11 Novartis AG Combinations of meningococcal factor h binding protein and pneumococcal saccharide conjugates
CA2759400A1 (en) 2009-04-30 2010-11-04 Children's Hospital & Research Center At Oakland Chimeric factor h binding proteins (fhbp) and methods of use
ITMI20090946A1 (it) 2009-05-28 2010-11-29 Novartis Ag Espressione di proteine ricombinanti
US8287880B2 (en) 2009-06-02 2012-10-16 National Health Research Institutes Lipidated vaccine against dengue virus infection
CA2765112A1 (en) 2009-06-10 2010-12-16 Novartis Ag Benzonaphthyridine-containing vaccines
WO2011008400A2 (en) 2009-06-16 2011-01-20 Novartis Ag High-throughput complement-mediated antibody-dependent and opsonic bactericidal assays
US8658176B2 (en) 2009-06-22 2014-02-25 National Health Research Institutes Lipidated tumor-associated antigens and immunotherapeutic compositions
CN102740882A (zh) 2009-08-27 2012-10-17 诺华有限公司 含有铝、寡核苷酸和聚阳离子的佐剂
US20110076300A1 (en) 2009-08-27 2011-03-31 Mariagrazia Pizza Hybrid Polypeptides Including Meningococcal fHBP Sequences
WO2011026111A1 (en) 2009-08-31 2011-03-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Oral delivery of a vaccine to the large intestine to induce mucosal immunity
ES2443952T3 (es) 2009-09-02 2014-02-21 Novartis Ag Composiciones inmunógenas que incluyen moduladores de la actividad de TLR
JO3257B1 (ar) 2009-09-02 2018-09-16 Novartis Ag مركبات وتركيبات كمعدلات لفاعلية tlr
US8974799B2 (en) 2009-09-30 2015-03-10 Novartis Ag Conjugation of Staphylococcus aureus type 5 and type 8 capsular polysaccharides
CN102724988B (zh) 2009-09-30 2014-09-10 诺华股份有限公司 脑膜炎球菌fHBP多肽的表达
CA2779816A1 (en) 2009-10-27 2011-05-05 Novartis Ag Modified meningococcal fhbp polypeptides
BR112012010223A2 (pt) 2009-10-30 2016-12-06 Novartis Ag purificação de staphylococcus aureus tipo 5 e tipo 8 sacarídeos capsulares
WO2011057148A1 (en) 2009-11-05 2011-05-12 Irm Llc Compounds and compositions as tlr-7 activity modulators
SG10201501980SA (en) 2009-12-15 2015-05-28 Novartis Ag Homogeneous suspension of immunopotentiating compounds and uses thereof
EP2545068B8 (en) 2010-03-11 2018-03-21 GlaxoSmithKline Biologicals S.A. Immunogenic composition or vaccine against gram-negative bacterial, for example neiserial, infection or disease
CN102802662A (zh) 2010-03-18 2012-11-28 诺华有限公司 用于脑膜炎球菌血清组b的含佐剂疫苗
AU2011232421B2 (en) 2010-03-23 2015-08-13 Novartis Ag Compounds (cystein based lipopeptides) and compositions as TLR2 agonists used for treating infections, inflammations, respiratory diseases etc.
ES2910199T3 (es) 2010-03-30 2022-05-11 Childrens Hospital & Res Center At Oakland Proteínas de unión al factor H (fHbp) con propiedades alteradas y métodos de uso de las mismas
AU2011237393B2 (en) 2010-04-08 2015-01-22 University Of Pittsburgh - Of The Commonwealth System Of Higher Education B-cell antigen presenting cell assay
KR20130121699A (ko) 2010-05-28 2013-11-06 테트리스 온라인, 인코포레이티드 상호작용 혼성 비동기 컴퓨터 게임 기반구조
CA2803239A1 (en) 2010-06-25 2011-12-29 Novartis Ag Combinations of meningococcal factor h binding proteins
KR101594228B1 (ko) 2010-08-23 2016-02-15 와이어쓰 엘엘씨 네이세리아 메닌기티디스 ｒＬＰ２０８６ 항원의 안정한 제제
GB201014967D0 (en) * 2010-09-09 2010-10-20 Univ Southampton Composition
BR112013005626B1 (pt) 2010-09-10 2022-07-26 Glaxosmithkline Biologicals Sa Meningococo, processo para a preparação de uma cepa meningocócica, vesículas de membrana externa, composição farmacêutica imunogênica, e, uso de uma composição
NZ607224A (en) 2010-09-10 2014-11-28 Wyeth Llc Non-lipidated variants of neisseria meningitidis orf2086 antigens
US20120070457A1 (en) * 2010-09-10 2012-03-22 J. Craig Venter Institute, Inc. Polypeptides from neisseria meningitidis
GB201101665D0 (en) 2011-01-31 2011-03-16 Novartis Ag Immunogenic compositions
TWI507413B (zh) 2010-11-15 2015-11-11 Nat Health Research Institutes 脂質化多抗原表位疫苗
TW201221642A (en) 2010-11-15 2012-06-01 Nat Health Research Institutes Method of producing lipidated polypeptides
WO2012085668A2 (en) 2010-12-24 2012-06-28 Novartis Ag Compounds
EP2491788B1 (en) 2011-02-25 2015-12-23 Kraft Foods R & D, Inc. Food product with a moulded body
WO2012117377A1 (en) 2011-03-02 2012-09-07 Novartis Ag Combination vaccines with lower doses of antigen and/or adjuvant
EP2707009A1 (en) 2011-05-12 2014-03-19 Novartis AG Antipyretics to enhance tolerability of vesicle-based vaccines
CN107837394A (zh) 2011-06-24 2018-03-27 埃皮托吉尼西斯有限公司 作为抗原特异性免疫调节剂的包含选择的载体、维生素、单宁和类黄酮的组合的药物组合物
CA2846290A1 (en) 2011-08-31 2013-03-07 Children's Hospital & Research Center Oakland Engineered sequences to facilitate expression of antigens in neisseria and methods of use
EP2776069A1 (en) 2011-11-07 2014-09-17 Novartis AG Carrier molecule comprising a spr0096 and a spr2021 antigen
EP2797624A1 (en) 2011-12-29 2014-11-05 Novartis AG Adjuvanted combinations of meningococcal factor h binding proteins
JP5957541B2 (ja) 2012-02-02 2016-07-27 ノバルティス アーゲー 髄膜炎菌における増加したタンパク質発現のためのプロモータ
JP2015517089A (ja) 2012-03-08 2015-06-18 ノバルティス アーゲー タンパク質ベースの髄膜炎菌ワクチンのためのインビトロ有効性アッセイ
CN104159603A (zh) 2012-03-08 2014-11-19 诺华股份有限公司 带有tlr4激动剂的联合疫苗
SA115360586B1 (ar) 2012-03-09 2017-04-12 فايزر انك تركيبات لعلاج الالتهاب السحائي البكتيري وطرق لتحضيرها
MX359256B (es) 2012-03-09 2018-09-19 Pfizer Composiciones de neisseria meningitidis y metodos de las mismas.
MX357538B (es) 2012-06-14 2018-07-13 Novartis Ag Vacunas para meningococo de serogrupo x.
AU2013295242C1 (en) 2012-07-27 2018-08-09 Institut National De La Sante Et De La Recherche Medicale CD147 as receptor for pilus-mediated adhesion of meningococci to vascular endothelia
US9526776B2 (en) 2012-09-06 2016-12-27 Glaxosmithkline Biologicals Sa Combination vaccines with serogroup B meningococcus and D/T/P
AR092897A1 (es) 2012-10-03 2015-05-06 Novartis Ag Composiciones inmunogenicas
AU2013344571A1 (en) * 2012-11-16 2015-06-04 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Gonorrheal MtrE peptides and vaccines
JP6411378B2 (ja) 2013-02-01 2018-10-24 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム Ｔｏｌｌ様受容体アゴニストを含む免疫学的組成物の皮内送達
US9802987B2 (en) 2013-03-08 2017-10-31 Pfizer Inc. Immunogenic fusion polypeptides
EA201690056A8 (ru) 2013-08-02 2017-07-31 Чилдренс Хоспитл Энд Рисерч Сентер Эт Окленд ИСКУССТВЕННЫЕ БЕЛКИ, СВЯЗЫВАЮЩИЕ ФАКТОР Н (fHbp), И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
RU2662968C2 (ru) 2013-09-08 2018-07-31 Пфайзер Инк. Иммуногенная композиция против neisseria meningitidis (варианты)
JP6786394B2 (ja) 2014-02-28 2020-11-18 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム 改変髄膜炎菌ｆＨｂｐポリペプチド
CA3212723A1 (en) 2014-07-23 2016-01-28 Peter T. Beernink Factor h binding protein variants and methods of use thereof
AU2016221318B2 (en) 2015-02-19 2020-06-25 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
EP3838918B1 (en) * 2015-05-18 2022-08-31 BiOMVis Srl Immunogenic compositions containing bacterial outer membrane vesicles and therapeutic uses thereof
BR112018017141A2 (pt) 2016-02-22 2019-01-02 Boehringer Ingelheim Vetmedica Gmbh método para a imobilização de biomoléculas
US11612664B2 (en) 2016-04-05 2023-03-28 Gsk Vaccines S.R.L. Immunogenic compositions
EP3263695A1 (en) 2016-06-29 2018-01-03 GlaxoSmithKline Biologicals SA Immunogenic compositions
US12161707B2 (en) 2016-09-02 2024-12-10 Glaxosmithkline Biologicals Sa Vaccines for Neisseria gonorrhoeae
AU2018215585B2 (en) 2017-01-31 2022-03-17 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
BR112020001255A2 (pt) 2017-07-21 2020-07-28 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services composições imunogênicas de neisseria meningitidis
US11116830B2 (en) 2017-12-18 2021-09-14 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Bacterial polysaccharide-conjugated carrier proteins and use thereof
ES2985591T3 (es) 2018-02-12 2024-11-06 Inimmune Corp Ligandos de receptores tipo Toll
CN108950056B (zh) * 2018-08-30 2021-08-20 安徽农业大学 与小麦种子休眠/穗发芽抗性相关的caps标记及其检测方法
WO2020086408A1 (en) 2018-10-26 2020-04-30 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services A high-yield perfusion-based transient gene expression bioprocess
CN113727722A (zh) * 2019-02-22 2021-11-30 伊夫罗生物科学公司 细菌膜制剂
GB2583070B (en) 2019-03-20 2023-09-13 Schlumberger Technology Bv Viscosification of aqueous solutions
US20230041432A1 (en) * 2019-03-21 2023-02-09 Fonterra Co-Operative Group Limited Compositions comprising polar lipids for maintaining or increasing mobility and vitality
EP4007600A4 (en) * 2019-08-01 2023-08-23 Trustees of Tufts College VACCINE COMPOSITION AND METHODS OF SELECTING ANTIGENS
EP4034157A1 (en) 2019-09-27 2022-08-03 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
JP7825273B2 (ja) * 2019-11-25 2026-03-06 グリフィス ユニバーシティー 淋菌感染症に対する免疫原性タンパク質
US11865981B2 (en) * 2020-05-05 2024-01-09 Thor Tech, Inc. Wire loom support
KR20230098825A (ko) 2020-11-04 2023-07-04 엘리고 바이오사이언스 씨. 아크네스 개체군에게 dna 페이로드의 원위치 전달을 위한 파지-유래 입자
CN113773366B (zh) * 2021-07-27 2023-06-16 四川丽妍工坊生物科技有限公司 一种抗炎多肽bmp14及其制备方法和应用
GB202115077D0 (en) 2021-10-21 2021-12-08 Glaxosmithkline Biologicals Sa Assay
GB202208089D0 (en) 2022-06-01 2022-07-13 Glaxosmithkline Biologicals Sa Immunogenic composition
GB202208093D0 (en) 2022-06-01 2022-07-13 Glaxosmithkline Biologicals Sa Immunogenic composition
WO2025006737A1 (en) 2023-06-30 2025-01-02 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Genetically detoxified mutant of neisseria and outer membrane vesicle (omv) vaccine
CN119020251A (zh) * 2024-08-26 2024-11-26 南昌大学 一株脂多糖修饰b群脑膜炎球菌与其外膜囊泡制备及应用

Family Cites Families (222)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2386796A (en) 1942-08-05 1945-10-16 Bond Crown & Cork Co Extruding device
DE2855719A1 (de) 1978-12-22 1980-07-10 Siemens Ag Zahnaerztliche handstueckanordnung
US4336336A (en) 1979-01-12 1982-06-22 President And Fellows Of Harvard College Fused gene and method of making and using same
AU545912B2 (en) 1980-03-10 1985-08-08 Cetus Corporation Cloned heterologous jive products in bacillies
ZA811368B (en) 1980-03-24 1982-04-28 Genentech Inc Bacterial polypedtide expression employing tryptophan promoter-operator
NZ199722A (en) 1981-02-25 1985-12-13 Genentech Inc Dna transfer vector for expression of exogenous polypeptide in yeast;transformed yeast strain
GR75411B (https=) 1981-04-29 1984-07-16 Biogen Nv
US4551433A (en) 1981-05-18 1985-11-05 Genentech, Inc. Microbial hybrid promoters
US4405712A (en) 1981-07-01 1983-09-20 The United States Of America As Represented By The Department Of Health And Human Services LTR-Vectors
US4769330A (en) 1981-12-24 1988-09-06 Health Research, Incorporated Modified vaccinia virus and methods for making and using the same
US4603112A (en) 1981-12-24 1986-07-29 Health Research, Incorporated Modified vaccinia virus
US4876197A (en) 1983-02-22 1989-10-24 Chiron Corporation Eukaryotic regulatable transcription
CA1341302C (en) 1983-02-22 2001-10-09 Rae Lyn Burke Yeast expression systems with vectors having gapdh or pyk promoters and synthesis of foreign protein
JPS59166086A (ja) 1983-03-09 1984-09-19 Teruhiko Beppu 新規な発現型プラスミドとそれらを用いて仔牛プロキモシン遺伝子を大腸菌内で発現させる方法
US4546083A (en) 1983-04-22 1985-10-08 Stolle Research & Development Corporation Method and device for cell culture growth
US4588684A (en) 1983-04-26 1986-05-13 Chiron Corporation a-Factor and its processing signals
JPS59205983A (ja) 1983-04-28 1984-11-21 ジエネツクス・コ−ポレイシヨン 異種遺伝子を原核微生物で発現させる方法
US4663280A (en) 1983-05-19 1987-05-05 Public Health Research Institute Of The City Of New York Expression and secretion vectors and method of constructing vectors
IE58011B1 (en) 1983-05-27 1993-06-16 Texas A & M Univ Sys Method for producing a recombinant baculovirus expression vector
US4689406A (en) 1983-08-10 1987-08-25 Amgen Enhancement of microbial expression of polypeptides
US4870008A (en) 1983-08-12 1989-09-26 Chiron Corporation Secretory expression in eukaryotes
JPS6054685A (ja) 1983-09-02 1985-03-29 Suntory Ltd 改良発現ベクタ−およびその利用
EP0136907A3 (en) 1983-10-03 1986-12-30 Genentech, Inc. A xenogeneic expression control system, a method of using it, expression vectors containing it, cells transformed thereby and heterologous proteins produced therefrom
ZA848495B (en) 1984-01-31 1985-09-25 Idaho Res Found Production of polypeptides in insect cells
US4880734A (en) 1984-05-11 1989-11-14 Chiron Corporation Eukaryotic regulatable transcription
DE3587759T2 (de) 1984-05-11 1994-07-07 Chiron Corp., Emeryville, Calif. Erhöhte Hefetranskription unter Verwendung einer Hybridkonstruktion der Promotorregion.
US5288641A (en) 1984-06-04 1994-02-22 Arch Development Corporation Herpes Simplex virus as a vector
CA1282721C (en) 1984-06-04 1991-04-09 Bernard Roizman Herpes simplex virus as a vector
US4738921A (en) 1984-09-27 1988-04-19 Eli Lilly And Company Derivative of the tryptophan operon for expression of fused gene products
US4745056A (en) 1984-10-23 1988-05-17 Biotechnica International, Inc. Streptomyces secretion vector
US4837148A (en) 1984-10-30 1989-06-06 Phillips Petroleum Company Autonomous replication sequences for yeast strains of the genus pichia
US4762915A (en) 1985-01-18 1988-08-09 Liposome Technology, Inc. Protein-liposome conjugates
US4797368A (en) 1985-03-15 1989-01-10 The United States Of America As Represented By The Department Of Health And Human Services Adeno-associated virus as eukaryotic expression vector
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
DE3679343D1 (de) 1985-03-28 1991-06-27 Chiron Corp Expression durch verwendung von fusionsgenen fuer proteinproduktion.
US4865974A (en) 1985-09-20 1989-09-12 Cetus Corporation Bacterial methionine N-terminal peptidase
US4777127A (en) 1985-09-30 1988-10-11 Labsystems Oy Human retrovirus-related products and methods of diagnosing and treating conditions associated with said retrovirus
JPS6296086A (ja) 1985-10-21 1987-05-02 Agency Of Ind Science & Technol 複合プラスミド
US5139941A (en) 1985-10-31 1992-08-18 University Of Florida Research Foundation, Inc. AAV transduction vectors
US5091309A (en) 1986-01-16 1992-02-25 Washington University Sindbis virus vectors
US4861719A (en) 1986-04-25 1989-08-29 Fred Hutchinson Cancer Research Center DNA constructs for retrovirus packaging cell lines
ATE110111T1 (de) 1986-05-02 1994-09-15 Gist Brocades Nv Sekretionssignal-selektionsvektoren für extrazelluläre proteinsynthese in bazillen.
US5554372A (en) 1986-09-22 1996-09-10 Emory University Methods and vaccines comprising surface-active copolymers
DE3752372T2 (de) 1986-10-02 2004-06-24 Massachusetts Institute Of Technology, Cambridge Verfahren zur regulierung der metabolischen stabilität von proteinen
EP0273116A3 (en) 1986-10-09 1990-05-02 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Gonococcal and meningococcal polypeptides, vaccines and diagnostics
US5514581A (en) * 1986-11-04 1996-05-07 Protein Polymer Technologies, Inc. Functional recombinantly prepared synthetic protein polymer
JPS63123383A (ja) 1986-11-11 1988-05-27 Mitsubishi Kasei Corp ハイブリツドプロモ−タ−、発現調節ｄｎａ配列および発現ベクタ−
GB8702816D0 (en) 1987-02-07 1987-03-11 Al Sumidaie A M K Obtaining retrovirus-containing fraction
US5219740A (en) 1987-02-13 1993-06-15 Fred Hutchinson Cancer Research Center Retroviral gene transfer into diploid fibroblasts for gene therapy
EP0284044B1 (en) 1987-03-23 1994-03-23 Zymogenetics, Inc. High level expression in yeast
US4980289A (en) 1987-04-27 1990-12-25 Wisconsin Alumni Research Foundation Promoter deficient retroviral vector
WO1989001973A2 (en) 1987-09-02 1989-03-09 Applied Biotechnology, Inc. Recombinant pox virus for immunization against tumor-associated antigens
DK463887D0 (da) 1987-09-07 1987-09-07 Novo Industri As Gaerleader
EP0378576B1 (en) 1987-09-11 1995-01-18 Whitehead Institute For Biomedical Research Transduced fibroblasts and uses therefor
US5124246A (en) 1987-10-15 1992-06-23 Chiron Corporation Nucleic acid multimers and amplified nucleic acid hybridization assays using same
US4929555A (en) 1987-10-19 1990-05-29 Phillips Petroleum Company Pichia transformation
NZ227011A (en) 1987-11-18 1992-03-26 Chiron Corp Non-a, non-b-hepatitis (hepatitis c) antigens, proteins, nucleotide sequences, vaccines and kits
JPH01144977A (ja) * 1987-11-30 1989-06-07 Agency Of Ind Science & Technol 新規組換えプラスミドｐＴＰＧＩＦ２
WO1989005349A1 (en) 1987-12-09 1989-06-15 The Australian National University Method of combating viral infections
CA1340772C (en) 1987-12-30 1999-09-28 Patricia Tekamp-Olson Expression and secretion of heterologous protiens in yeast employing truncated alpha-factor leader sequences
US4973551A (en) 1988-01-15 1990-11-27 Merck & Co., Inc. Vector for the expression of fusion proteins and protein immunogens
WO1989009271A1 (en) 1988-03-21 1989-10-05 Viagene, Inc. Recombinant retroviruses
US5662896A (en) 1988-03-21 1997-09-02 Chiron Viagene, Inc. Compositions and methods for cancer immunotherapy
US5591624A (en) 1988-03-21 1997-01-07 Chiron Viagene, Inc. Retroviral packaging cell lines
US5206152A (en) 1988-04-08 1993-04-27 Arch Development Corporation Cloning and expression of early growth regulatory protein genes
US5422120A (en) 1988-05-30 1995-06-06 Depotech Corporation Heterovesicular liposomes
AP129A (en) 1988-06-03 1991-04-17 Smithkline Biologicals S A Expression of retrovirus gag protein eukaryotic cells
CA1339354C (en) 1988-09-01 1997-08-26 The Whitehead Institute For Biomedical Research Recombinant retroviruses with amphotropic and ecotropic host ranges
JP3436756B2 (ja) 1988-12-19 2003-08-18 アメリカン・サイアナミド・カンパニー 髄膜炎菌のクラスｉの外膜タンパク質のワクチン
NL8803111A (nl) 1988-12-19 1990-07-16 Nederlanden Staat Multivalent meningococcen klasse i buitenmembraaneiwit vaccin.
US5217879A (en) 1989-01-12 1993-06-08 Washington University Infectious Sindbis virus vectors
JP2752788B2 (ja) 1989-01-23 1998-05-18 カイロン コーポレイション 感染および過剰増殖障害の為の組換え療法
WO1990009441A1 (en) 1989-02-01 1990-08-23 The General Hospital Corporation Herpes simplex virus type i expression vector
JP3140757B2 (ja) 1989-02-06 2001-03-05 デイナ・フアーバー・キヤンサー・インステイテユート パッケージング欠陥ｈｉｖプロウイルス、細胞系及びその使用
EP0463056A1 (en) 1989-03-17 1992-01-02 E.I. Du Pont De Nemours And Company External regulation of gene expression
ES2116269T3 (es) 1989-03-21 1998-07-16 Vical Inc Expresion de secuencias exogenas de polinucleotidos en un vertebrado.
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
HU212924B (en) 1989-05-25 1996-12-30 Chiron Corp Adjuvant formulation comprising a submicron oil droplet emulsion
ES2080153T3 (es) 1989-08-15 1996-02-01 Pasminco Australia Ltd Absorcion del vapor de cinc en el plomo fundido.
JP4041535B2 (ja) 1989-08-18 2008-01-30 オックスフォード バイオメディカ（ユーケー）リミテッド 標的細胞にベクター構造体を運搬する組換レトロウィルス
US5585362A (en) 1989-08-22 1996-12-17 The Regents Of The University Of Michigan Adenovirus vectors for gene therapy
US5166057A (en) 1989-08-28 1992-11-24 The Mount Sinai School Of Medicine Of The City University Of New York Recombinant negative strand rna virus expression-systems
GB8919607D0 (en) 1989-08-30 1989-10-11 Wellcome Found Novel entities for cancer therapy
AU7007491A (en) 1990-02-02 1991-08-08 Schweiz. Serum- & Impfinstitut Bern Cdna corresponding to the genome of negative-strand rna viruses, and process for the production of infectious negative-strand rna viruses
ZA911974B (en) 1990-03-21 1994-08-22 Res Dev Foundation Heterovesicular liposomes
CA2039921A1 (en) 1990-04-16 1991-10-17 Xandra O. Breakefield Transfer and expression of gene sequences into central nervous system cells using herpes simplex virus mutants with deletions in genes for viral replication
WO1991018088A1 (en) 1990-05-23 1991-11-28 The United States Of America, Represented By The Secretary, United States Department Of Commerce Adeno-associated virus (aav)-based eucaryotic vectors
US5149655A (en) 1990-06-21 1992-09-22 Agracetus, Inc. Apparatus for genetic transformation
CU22302A1 (es) * 1990-09-07 1995-01-31 Cigb Secuencia nucleotidica codificante para una proteina de la membrana externa de neisseria meningitidis y uso de dicha proteina en preparados vacunales
IE912559A1 (en) 1990-07-19 1992-01-29 Merck & Co Inc The class ii protein of the outer membrane of neisseria¹meningitidis, and vaccines containing same
EP0541693B1 (en) 1990-07-27 1998-12-09 Chiron Corporation Large comb-type branched polynucleotides
CA2087958C (en) * 1990-08-23 2007-05-15 P. Frederick Sparling Transferrin binding proteins from neisseria gonorrhoeae and neisseria meningitidis
EP1285967A3 (en) 1990-09-21 2005-03-02 Chiron Corporation Human retroviral packaging cell line
US5173414A (en) 1990-10-30 1992-12-22 Applied Immune Sciences, Inc. Production of recombinant adeno-associated virus vectors
WO1992007945A1 (en) 1990-10-30 1992-05-14 Dana Farber Cancer Institute Cell type specific alteration of levels of gene products in neural cells
SE9003978D0 (sv) 1990-12-13 1990-12-13 Henrik Garoff Dna expressionssystem baserade paa ett virus replikon
CA2098849C (en) 1990-12-20 2007-07-10 Dana-Farber Cancer Institute Control of gene expression by ionizing radiation
WO1992013871A1 (en) * 1991-01-31 1992-08-20 Washington University Polypeptides and polynucleotides useful for the diagnosis and treatment of pathogenic neisseria
JP3213313B2 (ja) 1991-03-14 2001-10-02 イムクローン システムズ インコーポレーテッド 組み換えハイブリッドポーリンエピトープ
IL101715A (en) 1991-05-02 2005-06-19 Amgen Inc Recombinant dna-derived cholera toxin subunit analogs
JPH0515375A (ja) * 1991-07-11 1993-01-26 Kanegafuchi Chem Ind Co Ltd ヒト内因子をコードするｄｎａ配列
JP3534749B2 (ja) 1991-08-20 2004-06-07 アメリカ合衆国 アデノウイルスが介在する胃腸管への遺伝子の輸送
FR2681786A1 (fr) 1991-09-27 1993-04-02 Centre Nat Rech Scient Vecteurs recombinants d'origine virale, leur procede d'obtention et leur utilisation pour l'expression de polypeptides dans des cellules musculaires.
NZ244306A (en) 1991-09-30 1995-07-26 Boehringer Ingelheim Int Composition for introducing nucleic acid complexes into eucaryotic cells, complex containing nucleic acid and endosomolytic agent, peptide with endosomolytic domain and nucleic acid binding domain and preparation
IL103059A0 (en) 1991-09-30 1993-02-21 Boehringer Ingelheim Int Conjugates for introducing nucleic acid into higher eucaryotic cells
US5252479A (en) 1991-11-08 1993-10-12 Research Corporation Technologies, Inc. Safe vector for gene therapy
WO1993010218A1 (en) 1991-11-14 1993-05-27 The United States Government As Represented By The Secretary Of The Department Of Health And Human Services Vectors including foreign genes and negative selective markers
GB9125623D0 (en) 1991-12-02 1992-01-29 Dynal As Cell modification
US5769047A (en) 1991-12-23 1998-06-23 Zoche; Michael Engine with oil separator
WO1993014778A1 (en) 1992-01-23 1993-08-05 Vical, Inc. Ex vivo gene transfer
WO1993015115A1 (en) 1992-01-24 1993-08-05 Cornell Research Foundation, Inc. E. coli dna polymerase iii holoenzyme and subunits
FR2688514A1 (fr) 1992-03-16 1993-09-17 Centre Nat Rech Scient Adenovirus recombinants defectifs exprimant des cytokines et medicaments antitumoraux les contenant.
EP0650370A4 (en) 1992-06-08 1995-11-22 Univ California METHODS AND COMPOSITIONS TARGETED ON SPECIFIC TISSUES.
CA2137361A1 (en) 1992-06-10 1993-12-23 W. French Anderson Vector particles resistant to inactivation by human serum
WO1993025685A1 (en) * 1992-06-12 1993-12-23 Massachusetts Institute Of Technology Cloning and characterization of the cell death genes ced-3 and ced-4
FR2692592B1 (fr) 1992-06-19 1995-03-31 Pasteur Merieux Serums Vacc Fragments d'ADN codant pour les sous-unités du récepteur de la transferrine de Neisseria meningitidis et procédés les exprimant.
GB2269175A (en) 1992-07-31 1994-02-02 Imperial College Retroviral vectors
GB9216851D0 (en) 1992-08-07 1992-09-23 Univ Manitoba Dna sequences of rat probasin gene
EP0669987B1 (en) 1992-09-25 2008-08-13 Aventis Pharma S.A. Adenovirus vectors for the transfer of foreign genes into cells of the central nervous system, particularly in brain
WO1994008013A1 (en) * 1992-10-07 1994-04-14 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education On Behalf Of The Oregon Health Sciences University Pilin variants and uses thereof
JPH08506008A (ja) 1992-11-18 1996-07-02 アーチ ディベロプメント コーポレイション 心筋及び血管平滑筋へのアデノウィルス介在遺伝子移入
AU680459B2 (en) 1992-12-03 1997-07-31 Genzyme Corporation Gene therapy for cystic fibrosis
US5478745A (en) 1992-12-04 1995-12-26 University Of Pittsburgh Recombinant viral vector system
US5348358A (en) 1993-02-22 1994-09-20 Selick David A Contact lens insertion tool
DE4311651A1 (de) 1993-04-08 1994-10-13 Boehringer Ingelheim Int Virus für den Transport von Fremd-DNA in höhere eukaryotische Zellen
PT695169E (pt) 1993-04-22 2003-04-30 Skyepharma Inc Lipossomas multivesiculares de ciclodextrina encapsulando compostos farmacologicos e metodos para a sua utilizacao
DK0624376T3 (da) 1993-05-13 2000-07-24 American Cyanamid Co Fremstilling og anvendelse af LOS-udtømte ydre membranproteiner af gram-negative cocci
CA2162271A1 (en) 1993-05-26 1994-12-08 Robert Kotin Fusion proteins containing adeno-associated virus rep protein and bacterial protein
FR2705686B1 (fr) 1993-05-28 1995-08-18 Transgene Sa Nouveaux adénovirus défectifs et lignées de complémentation correspondantes.
US6479055B1 (en) * 1993-06-07 2002-11-12 Trimeris, Inc. Methods for inhibition of membrane fusion-associated events, including respiratory syncytial virus transmission
ES2249761T3 (es) 1993-06-24 2006-04-01 Advec Inc. Vectores de adenovirus para terapia genica.
BR9405507A (pt) 1993-07-13 1999-05-25 Rhone Poulenc Rorer Sa Adenovirus recombinante defeituoso linhagem celular e composição farmaceutica
US5439808A (en) 1993-07-23 1995-08-08 North American Vaccine, Inc. Method for the high level expression, purification and refolding of the outer membrane group B porin proteins from Neisseria meningitidis
WO1995004139A1 (en) 1993-07-27 1995-02-09 The Wistar Institute Of Anatomy And Biology Modified dna virus vectors and uses therefor
US5631236A (en) 1993-08-26 1997-05-20 Baylor College Of Medicine Gene therapy for solid tumors, using a DNA sequence encoding HSV-Tk or VZV-Tk
US5362865A (en) 1993-09-02 1994-11-08 Monsanto Company Enhanced expression in plants using non-translated leader sequences
ES2328424T3 (es) 1993-09-15 2009-11-12 Novartis Vaccines And Diagnostics, Inc. Vectores de alfavirus recombinantes.
FR2710536B1 (fr) 1993-09-29 1995-12-22 Transgene Sa Usage anti-cancéreux d'un vecteur viral comportant un gène modulateur de la réponse immunitaire et/ou inflammatoire.
JPH09505561A (ja) 1993-10-01 1997-06-03 アメリカ合衆国 神経系の遺伝子治療
EP1637608B1 (en) 1993-10-25 2009-07-22 CANJI, Inc. Recombinant adenoviral vector and methods of use
US5693506A (en) 1993-11-16 1997-12-02 The Regents Of The University Of California Process for protein production in plants
PT729351E (pt) 1993-11-16 2000-12-29 Skyepharma Inc Vesiculas com libertacao controlada de activos
FR2712603B1 (fr) 1993-11-18 1996-02-09 Centre Nat Rech Scient Virus recombinants, préparation et utilisation en thérapie génique.
US5550213A (en) 1993-12-27 1996-08-27 Rutgers, The State University Of New Jersey Inhibitors of urokinase plasminogen activator
JPH07241786A (ja) 1994-03-08 1995-09-19 Fanuc Ltd 産業用ロボットの制御装置
US6780406B1 (en) 1994-03-21 2004-08-24 The Regents Of The University Of Michigan Inhibition of vascular smooth muscle cell proliferation administering a thymidine kinase gene
US7252989B1 (en) 1994-04-04 2007-08-07 Board Of Regents, The University Of Texas System Adenovirus supervector system
AU2356095A (en) 1994-04-20 1995-11-29 U.S. Department Of The Army Vaccine against gram-negative bacterial infections
CA2189067A1 (en) 1994-04-28 1995-11-09 Gary J. Nabel Gene delivery vector using plasmid dna packaged into an adenovirus and a packaging cell line
WO1995030763A2 (en) 1994-05-09 1995-11-16 Chiron Viagene, Inc. Retroviral vectors having a reduced recombination rate
FR2720408B1 (fr) 1994-05-31 1996-08-14 Pasteur Merieux Serums Vacc Fragments Tbp2 de Neisseria meningitidis.
JP3816518B2 (ja) 1994-06-10 2006-08-30 ジェンベク、インコーポレイティッド 相補的なアデノウイルスベクター系と細胞系
FR2722210B1 (fr) * 1994-07-08 1996-08-14 Rhone Poulenc Rorer Sa Nouvelles streptogramines et procede de preparation de streptogramines par mutasynthese
FR2723588B1 (fr) 1994-08-12 1996-09-20 Rhone Poulenc Rorer Sa Adenovirus comprenant un gene codant pour la glutathion peroxydase
IL117483A (en) 1995-03-17 2008-03-20 Bernard Brodeur MENINGITIDIS NEISSERIA shell protein is resistant to proteinase K.
US6265567B1 (en) * 1995-04-07 2001-07-24 University Of North Carolina At Chapel Hill Isolated FrpB nucleic acid molecule
AU5552396A (en) * 1995-04-21 1996-11-07 Human Genome Sciences, Inc. Nucleotide sequence of the haemophilus influenzae rd genome, fragments thereof, and uses thereof
JPH11505128A (ja) 1995-05-22 1999-05-18 カイロン コーポレイション キメラインテグラーゼタンパク質に媒介される真核生物ゲノム中へのベクター構築物の位置特異的組み込み
WO1996040893A1 (en) * 1995-06-07 1996-12-19 Astra Aktiebolag Nucleic acid and amino acid sequences relating to helicobacter pylori for diagnostics and therapeutics
FR2739624B1 (fr) * 1995-10-10 1997-12-05 Pasteur Merieux Serums Vacc Nouvelle sous-unite tbp2 de neisseria meningitidis
US6737248B2 (en) * 1996-01-05 2004-05-18 Human Genome Sciences, Inc. Staphylococcus aureus polynucleotides and sequences
WO1997027300A1 (en) * 1996-01-26 1997-07-31 Innogenetics N.V. TOXOPLASMA GONDII ANTIGEN Tg20
HUP9901039A2 (hu) 1996-02-01 1999-07-28 North American Vaccine, Inc. Neisseria meningitidis B-csoportba tartozó külső-membrán-fehérjéjének (MB3) expressziója élesztőben, továbbá vakcinák
US5753235A (en) 1996-02-15 1998-05-19 Heska Corporation Recombinant canine herpesviruses
IL125808A0 (en) 1996-03-29 1999-04-11 Astra Ab Nucleic acid and amino acid sequences relating to helicobacter pylori and vaccine compositions thereof
CN1236320A (zh) * 1996-05-10 1999-11-24 爱克斯欧玛公司 杀菌的/增强通透性的蛋白质产物用于人脑膜炎球菌血症的治疗用途
US6096529A (en) * 1996-06-10 2000-08-01 National Research Council Of Canada Recombinant α-2,3-sialyltransferases and their uses
EP0818465A1 (en) * 1996-07-12 1998-01-14 Institute of Molecular Biotechnology (IMB) Department of Genome Analysis Genomic sequence of Rhizobium sp. NGR234 symbiotic plasmid
FR2751000B1 (fr) * 1996-07-12 1998-10-30 Inst Nat Sante Rech Med Adn specifiques des bacteries de l'espece neisseria meningitidis, leurs procedes d'obtention et leurs applications biologiques
AU5426098A (en) * 1996-10-24 1998-05-15 Emory University Invasion associated genes from (neisseria meningitidis) serogroup
KR100615109B1 (ko) * 1996-12-20 2006-08-22 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 모렉셀라 카타르할리스의 ｕｓｐａ1, ｕｓｐａ2 항원
US5763589A (en) * 1997-01-09 1998-06-09 Incyte Pharmaceuticals, Inc. Human membrane protein
US6914131B1 (en) 1998-10-09 2005-07-05 Chiron S.R.L. Neisserial antigens
CN1263854C (zh) * 1997-11-06 2006-07-12 启龙股份公司 奈瑟球菌抗原
GB9726398D0 (en) 1997-12-12 1998-02-11 Isis Innovation Polypeptide and coding sequences
AU1979599A (en) 1998-01-14 1999-08-02 Chiron S.P.A. (neisseria meningitidis) antigens
EP2261352A3 (en) * 1998-05-01 2012-01-04 Novartis Vaccines and Diagnostics, Inc. Neisseria meningitidis antigens and compositions
US20070026021A1 (en) 1998-05-01 2007-02-01 Chiron S.R.I. Neisseria meningitidis antigens and compositions
BR9914374A (pt) 1998-10-09 2002-09-17 Chiron Corp Sequências genÈmicas de neisseria e métodos para seu uso
US6214566B1 (en) * 1998-11-16 2001-04-10 The Administrators Of The Tulane Educational Fund Method for detecting anti-squalene antibodies
ATE527360T1 (de) * 1998-12-08 2011-10-15 Glaxosmithkline Biolog Sa Neue verbindungen abgeleitet von neisseria meningitidis
GB9902084D0 (en) * 1999-01-29 1999-03-24 Smithkline Beecham Biolog Novel compounds
CA2365102A1 (en) * 1999-03-12 2000-09-21 Smithkline Beecham Biologicals S.A. Neisseria meningitidis antigenic polypeptides and encoding polynucleotides and uses thereof
JP2003518363A (ja) * 1999-04-30 2003-06-10 カイロン エセ．ピー．アー． 保存されたナイセリア抗原
CN101033467A (zh) 1999-04-30 2007-09-12 希龙公司 奈瑟球菌基因组序列及其用法
EP2270173B1 (en) * 1999-05-19 2016-01-06 GlaxoSmithKline Biologicals SA Combination neisserial compositions
RU2281956C2 (ru) 1999-10-29 2006-08-20 Чирон С.Р.Л. Антигенные пептиды neisseria
PT2289545T (pt) 2000-01-17 2016-09-06 Glaxosmithkline Biologicals Sa Vacina de omv suplementada contra meningococos
PL216780B1 (pl) 2000-01-25 2014-05-30 Univ Queensland Of Santa Lucia Wyizolowane białka zawierające konserwatywne obszary antygenu powierzchniowego NhhA z Neisseria meningitidis, białka fuzyjne, kompozycja farmaceutyczna, przeciwciało monoklonalne lub wiążący antygen fragment przeciwciała monoklonalnego, wyizolowany kwas nukleinowy, konstrukt ekspresyjny, komórka gospodarza, sposób wytwarzania rekombinowanego białka, sposób wykrywania N. meningitidis w próbce biologicznej, sposób diagnozowania zakażenia N. meningitidis oraz sposób wykrywania N. meningitidis w próbce biologicznej uzyskanej od pacjenta oraz zastosowanie wyizolowanego białka, białka fuzyjnego i konstruktu ekspresyjnego
ES2281409T3 (es) 2000-02-28 2007-10-01 Novartis Vaccines And Diagnostics S.R.L. Expresion heterologa de proteinas de neisseria.
DK1282702T3 (da) 2000-05-10 2007-04-02 Sanofi Pasteur Ltd Immunogene polypeptider, som er kodet af KAGE-minigener, og anvendelser deraf
GB0118249D0 (en) 2001-07-26 2001-09-19 Chiron Spa Histidine vaccines
CA2452720C (en) 2001-07-26 2012-04-17 Chiron S.R.L. Vaccines comprising aluminium adjuvants and histidine
GB0121591D0 (en) 2001-09-06 2001-10-24 Chiron Spa Hybrid and tandem expression of neisserial proteins
BR0211494A (pt) 2001-07-27 2004-08-17 Chiron Srl Adesinas de meningococo nada, app e orf 40
MX339524B (es) 2001-10-11 2016-05-30 Wyeth Corp Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica.
EP1524991A1 (en) 2002-08-02 2005-04-27 GlaxoSmithKline Biologicals S.A. Vaccine composition comprising transferrin binding protein and hsf from gram negative bacteria
US7785608B2 (en) 2002-08-30 2010-08-31 Wyeth Holdings Corporation Immunogenic compositions for the prevention and treatment of meningococcal disease
HUE031886T2 (en) 2002-10-11 2017-08-28 Glaxosmithkline Biologicals Sa Polypeptide vaccines for extensive protection against hypervirulent meningococcal lines
GB0227346D0 (en) 2002-11-22 2002-12-31 Chiron Spa 741
CA2512917A1 (en) 2003-01-15 2004-08-05 Wyeth Holdings Corporation Methods for increasing neisseria protein expression
ES2461350T3 (es) 2003-01-30 2014-05-19 Novartis Ag Vacunas inyectables contra múltiples serogrupos de meningococos
MXPA05011110A (es) 2003-04-16 2006-01-24 Wyeth Corp Composiciones inmunogenicas novedosas para la prevencion y tratamiento de un padecimiento originado por meningococos.
CN103357002A (zh) 2003-10-02 2013-10-23 诺华疫苗和诊断有限公司 多种脑膜炎球菌血清群的液体疫苗
GB0409748D0 (en) 2004-04-30 2004-06-09 Chiron Srl Lactoferrin cleavage
GB0419408D0 (en) 2004-09-01 2004-10-06 Chiron Srl 741 chimeric polypeptides
ES2616294T3 (es) 2005-01-27 2017-06-12 Children's Hospital & Research Center At Oakland Vacunas de vesículas basadas en GNA1870 para protección de amplio espectro contra enfermedades provocadas por Neisseria meningitidis
GB0524066D0 (en) 2005-11-25 2006-01-04 Chiron Srl 741 ii
TW200806315A (en) 2006-04-26 2008-02-01 Wyeth Corp Novel formulations which stabilize and inhibit precipitation of immunogenic compositions
CA2656474A1 (en) * 2006-06-29 2008-01-03 Novartis Ag Polypeptides from neisseria meningitidis
AR064642A1 (es) 2006-12-22 2009-04-15 Wyeth Corp Polinucleotido vector que lo comprende celula recombinante que comprende el vector polipeptido , anticuerpo , composicion que comprende el polinucleotido , vector , celula recombinante polipeptido o anticuerpo , uso de la composicion y metodo para preparar la composicion misma y preparar una composi
WO2008125985A2 (en) 2007-04-11 2008-10-23 Novartis Ag Blocking interaction between pathogen factors and factor h to inhibit hemorrhagic syndromes
CA2688268A1 (en) 2007-06-04 2008-12-11 Novartis Ag Formulation of meningitis vaccines
CN102356089B (zh) 2008-02-21 2014-02-19 诺华股份有限公司 脑膜炎球菌fHBP多肽
ES2557282T3 (es) 2008-03-10 2016-01-25 Children's Hospital & Research Center At Oakland Proteínas quiméricas de unión al factor H (fHBP) que contienen un dominio B heterólogo, y métodos de uso
WO2010028096A2 (en) 2008-09-03 2010-03-11 Children's Hospital & Research Center At Oakland Peptides presenting an epitope of an a domain of factor h binding protein and methods of use
IT1394288B1 (it) 2008-09-12 2012-06-06 Novartis Vaccines & Diagnostic Immunogeni di proteine che legano il fattore h.
GB0819633D0 (en) 2008-10-25 2008-12-03 Isis Innovation Composition
WO2010065473A2 (en) 2008-12-01 2010-06-10 Applied Materials, Inc. Gas distribution blocker apparatus
HUE049695T2 (hu) 2009-03-24 2020-10-28 Glaxosmithkline Biologicals Sa Adjuváló H meningococcus faktort kötõ fehérje
BR112013005626B1 (pt) 2010-09-10 2022-07-26 Glaxosmithkline Biologicals Sa Meningococo, processo para a preparação de uma cepa meningocócica, vesículas de membrana externa, composição farmacêutica imunogênica, e, uso de uma composição

Also Published As

Publication number Publication date
EP2261340A2 (en) 2010-12-15
JP2016222709A (ja) 2016-12-28
EP2261346A2 (en) 2010-12-15
CN100379757C (zh) 2008-04-09
EP2261355A2 (en) 2010-12-15
EP2261347A3 (en) 2012-01-11
EP1645631A3 (en) 2006-04-19
DE69937419T2 (de) 2008-07-24
NZ527182A (en) 2004-06-25
NZ532665A (en) 2005-11-25
CN101293920A (zh) 2008-10-29
JP2012191946A (ja) 2012-10-11
ES2294629T3 (es) 2008-04-01
EP2261356A2 (en) 2010-12-15
EP2261351A2 (en) 2010-12-15
EP2261339A2 (en) 2010-12-15
WO1999057280A2 (en) 1999-11-11
PT1093517E (pt) 2008-06-12
EP1944371A2 (en) 2008-07-16
EP2261343A3 (en) 2012-01-18
CY1109649T1 (el) 2014-08-13
DE69937419D1 (de) 2007-12-06
US20090232820A1 (en) 2009-09-17
US9266929B2 (en) 2016-02-23
ATE376591T1 (de) 2007-11-15
WO1999057280A9 (en) 2002-08-29
ATE388230T1 (de) 2008-03-15
EP2261342A3 (en) 2012-01-04
HK1090382A1 (zh) 2006-12-22
US20120135024A1 (en) 2012-05-31
EP1944371B1 (en) 2015-03-04
EP2261340A3 (en) 2012-01-04
EP2261344A2 (en) 2010-12-15
JP2012191945A (ja) 2012-10-11
EP2261339A3 (en) 2012-01-11
EP2261354A3 (en) 2012-01-11
PT1645631E (pt) 2008-02-04
EP2261341A3 (en) 2012-01-04
CN101293920B (zh) 2012-07-18
EP2261355A3 (en) 2012-01-11
EP2261340B1 (en) 2017-03-08
DK1093517T3 (da) 2008-06-23
US20120148616A1 (en) 2012-06-14
EP2261349A2 (en) 2010-12-15
JP5102414B2 (ja) 2012-12-19
EP2261354A2 (en) 2010-12-15
EP2261338A3 (en) 2012-01-04
EP2261342A2 (en) 2010-12-15
CN1754885A (zh) 2006-04-05
EP2261349A3 (en) 2012-01-11
EP2261348A3 (en) 2012-01-25
EP2261344A3 (en) 2012-01-04
EP2261347A2 (en) 2010-12-15
CN1210305C (zh) 2005-07-13
PT1944371E (pt) 2015-07-13
CY1108083T1 (el) 2014-02-12
EP2261357A3 (en) 2012-01-11
JP2010166916A (ja) 2010-08-05
EP2261356A3 (en) 2012-01-04
ES2537575T3 (es) 2015-06-09
CA2330838A1 (en) 1999-11-11
EP1645631B1 (en) 2007-10-24
NZ541361A (en) 2008-04-30
JP2004500801A (ja) 2004-01-15
EP1944371A3 (en) 2008-10-08
US9249196B2 (en) 2016-02-02
EP2261341A2 (en) 2010-12-15
JP2013255503A (ja) 2013-12-26
US9139621B2 (en) 2015-09-22
EP2261345A3 (en) 2012-01-11
JP2017012195A (ja) 2017-01-19
US20120164166A1 (en) 2012-06-28
US9249198B2 (en) 2016-02-02
EP2261348A2 (en) 2010-12-15
BR9910089A (pt) 2004-06-08
DK1645631T3 (da) 2008-02-18
MX343744B (es) 2016-11-22
DE69938302D1 (de) 2008-04-17
JP6025674B2 (ja) 2016-11-16
JP2009183306A (ja) 2009-08-20
EP2261338A2 (en) 2010-12-15
EP2261350A2 (en) 2010-12-15
EP2261339B1 (en) 2017-03-22
EP2261351A3 (en) 2012-01-11
EP2261346A3 (en) 2012-01-04
EP2261357A2 (en) 2010-12-15
EP2261350A3 (en) 2012-01-04
AU3967799A (en) 1999-11-23
EP1645631A2 (en) 2006-04-12
MXPA00010722A (es) 2004-12-03
US20120156236A1 (en) 2012-06-21
US7988979B2 (en) 2011-08-02
NZ508366A (en) 2004-03-26
WO1999057280A3 (en) 2000-08-24
CN1373806A (zh) 2002-10-09
US20150086582A1 (en) 2015-03-26
EP2261353A3 (en) 2012-01-18
US20160030545A1 (en) 2016-02-04
EP1093517A2 (en) 2001-04-25
ES2304065T3 (es) 2008-09-01
EP2261353A2 (en) 2010-12-15
EP2261352A2 (en) 2010-12-15
JP2013252140A (ja) 2013-12-19
US7576176B1 (en) 2009-08-18
US8524251B2 (en) 2013-09-03
US20150079124A1 (en) 2015-03-19
EP2261343A2 (en) 2010-12-15
EP1093517B1 (en) 2008-03-05
CA2650642A1 (en) 1999-11-11
MX339406B (es) 2016-05-25
DE69938302T2 (de) 2009-03-12
JP6025675B2 (ja) 2016-11-16
MX343752B (es) 2016-11-22
EP2261345A2 (en) 2010-12-15
EP2261352A3 (en) 2012-01-04
AU761780B2 (en) 2003-06-12

Similar Documents

Publication Publication Date Title
CA2330838C (en) Neisseria meningitidis antigens and compositions
EP1185691B1 (en) Neisseria genomic sequences and methods of their use
US7714121B2 (en) Meningococcal antigens
EP1559795A2 (en) Neisseria genomic sequences and methods of their use
US20070026021A1 (en) Neisseria meningitidis antigens and compositions
AU2012203235B2 (en) Neisseria meningitidis antigens and compositions
AU2006202355B2 (en) Neisseria meningitidis antigens and compositions
AU2003235364B2 (en) Neisseria meningitidis antigens and compositions
HK1030435B (en) Neisseria meningitidis antigens

Legal Events

Date Code Title Description
EEER Examination request
MKEX Expiry

Effective date: 20190430